Companies › Zai Lab (Shanghai)
4 active drug programs in 6 registered trials: 4 Phase 1, 2 Phase 3; Oncology, Ophthalmology, Immunology; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ZL-1109 (VRDN-003) IGF-1 receptor antagonist | IGF1R | Phase 3 | Thyroid Eye Disease (TED) | Mar 2027 |
| ZL-1310 | – | Phase 3 | Small-cell Lung Cancer; SCLC; Solid Tumors | May 2027 |
| ZL-1503 | – | Phase 1 | Atopic Dermatitis (AD) | Dec 2027 |
| ZL-6201 | – | Phase 1 | Solid Tumors | Aug 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07211776 | ZL-1109 (VRDN-003) | Phase 3 | Thyroid Eye Disease (TED) | Ophthalmology | Mar 2027 |
| NCT06179069 | ZL-1310 | Phase 1 | SCLC | Oncology | May 2027 |
| NCT06885281 | ZL-1310 | Phase 1 | Solid Tumors | Oncology | Aug 2027 |
| NCT07235384 | ZL-1503 | Phase 1 | Atopic Dermatitis (AD) | Immunology | Dec 2027 |
| NCT07218146 | ZL-1310 | Phase 3 | Small-cell Lung Cancer | Oncology | Jun 2028 |
| NCT07374848 | ZL-6201 | Phase 1 | Solid Tumors | Oncology | Aug 2028 |
Cash and short-term investments of $560m on 2026-09-30; operating cash outflow about $179m a year; runway about 38 months at that burn, to Nov 2029; 2 of 2 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 3 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Innovent Biologics (Suzhou) OHB Neonatology Amgen Candid Therapeutics Viridian Therapeutics Minghui Pharmaceutical (Hangzhou) Sling Therapeutics
Minghui Pharmaceutical (Hangzhou) Corvus Pharmaceuticals Nuvation Bio Ascentage Pharma Group Sellas Life Sciences Group
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.